September 5, 2016
(STAT News) – The idea is tantalizing: Reengineer a patient’s own immune cells to attack the cancer that’s killing her. Scientists have proven it can be done, curing patients of otherwise terminal blood cancers. But faith in this approach, dubbed CAR-T immunotherapy, has been shaken in recent months.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.